Novartis India Limited: Building a branded pharma platform after ChrysCapital takeover
Insufficient data to meet the blogpost requirements as specified. The documents provide strategic commentary and limited financial history but do not provide quarter-specific headline metrics like EBITDA and do not provide enough granular financial disclosures to support the required 1300-1500 word analytical MDX blogpost with meaningful tables without inference.
Know Novartis India inside out
Results, valuation, peers and who's buying, in one view.
Frequently Asked Questions
As of August 28, 2026, the ChrysCapital Group holds 71% of the company, retail shareholders hold 26%, and institutions and government hold 3%.
The investor presentation reported revenue of INR 379 crore (FY23), INR 335 crore (FY24), INR 356 crore (FY25), and INR 354 crore (FY26). Profit after tax was INR 103 crore (FY23), INR 85 crore (FY24), INR 101 crore (FY25), and INR 93 crore (FY26).
The company highlighted that trademarks such as Voveran, Macalvit, and Citromacalvit have been assigned to the company, and that Tegrital is licensed with an automatic assignment mechanism under the brand license deed.
NIL acquired rights to use the Minipress trademark from Pfizer for INR 1,250 crore. The presentation cited Minipress XL MAT Jul 2026 revenue of about INR 228 crore (IQVIA TSA MAT Jul 26).
Management stated hiring is underway and expects the team to be fully operational and in-market by the end of Q3 FY27, with full costs reflected from Q4 FY27.
Management indicated an upfront investment phase where field force costs run ahead of current scale, and one-time impacts in Q2 to Q4 FY27 related to partnership termination and sales returns as the company shifts to an in-house model.